Inventor · disambiguated record
Martin Oft
Also filed as: OFT MARTIN
18 granted patents·21 pending applications·159 citations·filing 1997–2023
93Inventor score
Top patents by PatentIndex Score
39 records- 0194US7282204B2Uses of IL-23 agonists and antagonists; related reagentsSCHERING CORP·Filed 2004·Granted Oct 16, 2007·58 cites·11 claims
- 0293US10143726B2Methods of using interleukin-10 for treating diseases and disordersARMO BIOSCIENCES INC·Filed 2015·Granted Dec 4, 2018·18 cites·24 claims
- 0390US11491205B2Biased IL2 muteins methods and compositionsSYNTHEKINE INC·Filed 2021·Granted Nov 8, 2022·4 cites·18 claims
- 0490US9364517B2Method of treatment of lymphoma with pegylated IL-10MERCK SHARP & DOHME·Filed 2014·Granted Jun 14, 2016·14 cites·16 claims
- 0587US8865652B2Method of treating solid cancers with pegylated IL-10OFT MARTIN·Filed 2010·Granted Oct 21, 2014·14 cites·19 claims
- 0684US9970944B2Methods of modulating cytokine activity; related reagentsMERCK SHARP & DOHME·Filed 2014·Granted May 15, 2018·5 cites·8 claims
- 0780US10357545B2Methods of using interleukin-10 for treating solid tumorsARMO BIOSCIENCES INC·Filed 2018·Granted Jul 23, 2019·2 cites·12 claims
- 0880US9833514B2Use of pegylated IL-10 to treat cancerMERCK SHARP & DOHME·Filed 2016·Granted Dec 5, 2017·2 cites·8 claims
- 0976US9943568B2Methods of using pegylated interleukin-10 for treating cancerARMO BIOSCIENCES INC·Filed 2014·Granted Apr 17, 2018·2 cites·16 claims
- 1076US8034341B2Methods of inhibiting tumor growth using blocking antibodies to IL-23RSCHERING CORP·Filed 2009·Granted Oct 11, 2011·1 cites·9 claims
- 1176US6383733B1Methods of screening for pharmacologically active compounds for the treatment of tumour diseasesBOEHRINGER INGELHEIM INT·Filed 1997·Granted May 7, 2002·39 cites·14 claims
- 1275US12440540B2IL-2 orthologs and methods of useSYNTHEKINE INC·Filed 2023·Granted Oct 14, 2025·0 cites·8 claims
- 1366US10653751B2Methods of treating cancer metastasis by using interleukin-10ARMO BIOSCIENCES INC·Filed 2018·Granted May 19, 2020·0 cites·24 claims
- 1466US8822405B2Uses of mammalian cytokines and agonists; related reagentsOFT MARTIN·Filed 2009·Granted Sep 2, 2014·0 cites·2 claims
- 1565US2009214471A1Use of pegylated il-10 to treat cancerSCHERING CORP·Filed 2009·Application pending·0 cites
- 1664US2009041718A1Methods of Modulating Cytokine Activity; Related ReagentsSCHERING CORP·Filed 2008·Application pending·0 cites
- 1763US10568968B2Methods for treatment of cancer with therapeutic combinations comprising PEG-IL-10MERCK SHARP & DOHME·Filed 2017·Granted Feb 25, 2020·0 cites·3 claims
- 1862US11648296B2IL-2 orthologs and methods of useSYNTHEKINE INC·Filed 2020·Granted May 16, 2023·0 cites·2 claims
- 1962US2008057058A1Uses of il-23 agonists and antagonists; related reagentsSCHERING CORP·Filed 2007·Application pending·0 cites
- 2062US2023031597A1Biased il2 muteins methods and compositionsSYNTHEKINE INC·Filed 2022·Application pending·0 cites
- 2162US2008081031A1Use of Pegylated IL-10 to Treat CancerSCHERING CORP·Filed 2007·Application pending·0 cites
- 2260US2007160579A1Methods of modulating a mammalian cytokineSCHERING CORP·Filed 2007·Application pending·0 cites
- 2360US2018128837A1Methods of modulating cytokine activity; related reagentsMERCK SHARP & DOHME·Filed 2017·Application pending·0 cites
- 2458US2019314456A1Methods of using interleukin-10 for treating diseases and disordersARMO BIOSCIENCES INC·Filed 2019·Application pending·0 cites
- 2558US2025288666A1Methods and compositions for use in cell therapy of neoplastic diseaseSYNTHEKINE INC·Filed 2022·Application pending·0 cites
- 2658US2014370025A1Uses of mammalian cytokines and agonists; related reagentsMERCK SHARP & DOHME·Filed 2014·Application pending·0 cites
- 2757US11413332B2Methods of using interleukin-10 for treating diseases and disordersLILLY CO ELI·Filed 2014·Granted Aug 16, 2022·0 cites·20 claims
- 2855US2005203046A1Methods of modulating a mammalian cytokineSCHERING CORP·Filed 2005·Application pending·0 cites
- 2955US2020353050A1Compositions and methods of use of interleukin-10 in combination with immune check-point pathway inhibitorsARMO BIOSCIENCES INC·Filed 2018·Application pending·0 cites
- 3054US2005048061A1Uses of mammalian cytokines and agonists; related reagentsFiled 2004·Application pending·0 cites
- 3153US2012034219A1Uses of il-23 agonists and antagonists; related reagentsOFT MARTIN·Filed 2011·Application pending·0 cites
- 3251US2023374454A1Human immune cells genomically modified to express orthogonal receptorsSYNTHEKINE INC·Filed 2021·Application pending·0 cites
- 3349US2023076768A1IL2 Orthologs and Methods of UseSYNTHEKINE INC·Filed 2021·Application pending·0 cites
- 3449US2021347842A1Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapyLILLY CO ELI·Filed 2019·Application pending·0 cites
- 3548US2023159892A1Engineered immune cellsSYNTHEKINE INC·Filed 2021·Application pending·0 cites
- 3646US11814679B2Interleukin-10 production of antigen-specific CD8+ T cells and methods of use of sameLILLY CO ELI·Filed 2017·Granted Nov 14, 2023·0 cites·13 claims
- 3744US2002127542A1Pharmaceutical compositions for treating tumour diseasesBOEHRINGER INGELHEIM INT·Filed 2002·Application pending·0 cites
- 3837US2019307849A1Methods of using interleukin-10 for treating diseases and disordersARMO BIOSCIENCES INC·Filed 2016·Application pending·0 cites
- 3936US2016375101A1Methods of Using Interleukin-10 for Treating Diseases and DisordersARMO BIOSCIENCES INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Martin Oft files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →